NEW YORK (GenomeWeb News) - Oxford Genome Sciences said last weekthat it is collaborating with Amgen to discover, develop, and commercialize therapeutic antibodies for cancer.
 
The companies will use Amgen’s XenoMouse technology to generate fully human anibodies, which will be raised against druggable targets that Oxford Genome Sciences has identified through its Oxford Genome Anatomy Project database of cancer proteins.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.